Primary site as a novel prognostic factor for cardiovascular mortality post-radiotherapy in limited-stage small cell lung cancer: A large population-based study

Yuwei Zhao; Fen Qin; Qingqi Ji; Wuyan Xia; Ben He

doi:10.3389/fcvm.2022.922811

Primary site as a novel prognostic factor for cardiovascular mortality post-radiotherapy in limited-stage small cell lung cancer: A large population-based study

Front Cardiovasc Med. 2022 Aug 12:9:922811. doi: 10.3389/fcvm.2022.922811. eCollection 2022.

Authors

Yuwei Zhao¹, Fen Qin², Qingqi Ji¹, Wuyan Xia³, Ben He^{1

4}

Affiliations

¹ Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
² Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
³ Department of Radiation Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
⁴ Clinical Research Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Abstract

Background: The effect of primary site on cardiovascular mortality (CVM) post-radiotherapy (RT) in patients with limited-stage small cell lung cancer (LS-SCLC) remains unclear.

Methods: We screened the Surveillance, Epidemiology, and End Results (SEER) database between 1988 and 2013. We used cumulative incidence function (CIF) curves to compare CVM incidences, and performed Cox proportional hazards and Fine-Gray competing risk analyses to identify independent risk factors of CVM. Propensity score matching (PSM) analysis was conducted.

Results: Among enrolled 4,824 patients (median age 57 years old, 49.2% were male), CVM accounts for 10.0% of all deaths after 5 years since cancer diagnosis. Hazard ratios (HRs) for CVM were 1.97 (95% CI: 1.23-3.16, P = 0.005) for main bronchus (MB) patients, 1.65 (95% CI: 1.04-2.63, P = 0.034) for lower lobe (LL) patients and 1.01 (95% CI: 0.40-2.59, P = 0.977) for middle lobe (ML) patients compared to upper lobe (UL) patients. CIF curves showed that the cumulative CVM incidence was greater in the re-categorized MB/LL group compared to UL/ML group both before PSM (P = 0.005) and after PSM (P = 0.012). Multivariate regression models indicated that MB/LL was independently associated with an increased CVM risk, before PSM (HR_Cox: 1.79, 95% CI: 1.23-2.61, P = 0.002; HR_Fine-Gray: 1.71, 95% CI: 1.18-2.48, P = 0.005) and after PSM (HR_Cox: 1.88, 95% CI: 1.20-2.95, P = 0.006; HR_Fine-Gray: 1.79, 95% CI: 1.15-2.79, P = 0.010).

Conclusions: MB/LL as the primary site is independently associated with an increased CVM risk post-RT in patients with LS-SCLC.

Keywords: SEER; cardiovascular mortality; radiotherapy; small cell lung cancer; tumor primary site.